A Decade of Precision: PK/PD-Guided Eculizumab Therapy for TA-TMA Management

Key Points

• Eculizumab therapy improves clinical outcomes in TA-TMA management, demonstrating a precision medicine approach.
• Evaluation over a decade confirms the effectiveness of PK/PD modeling to optimize treatment interventions.
• Observational analysis highlights the role of biomarkers in personalizing eculizumab therapy for better results.
• Utilizing PK/PD modeling, this approach may enhance patient outcomes, though more studies are needed for broader applicability.